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Assessment of Lower-limb Vascular 
Endothelial Function Based on 
Enclosed Zone Flow-mediated 
Dilation
Harutoyo Hirano  1, Renjo Takama2, Ryo Matsumoto2, Hiroshi Tanaka2, Hiroki Hirano2,  
Zu Soh  3, Teiji Ukawa4, Tsuneo Takayanagi4, Haruka Morimoto4, Ryuji Nakamura  5, 
Noboru Saeki  5, Haruki Hashimoto6, Shogo Matsui6, Shinji Kishimoto  7, Nozomu Oda6, 
Masato Kajikawa7, Tatsuya Maruhashi6, Masashi Kawamoto5, Masao Yoshizumi8,  
Yukihito Higashi7,9 & Toshio Tsuji3
This paper proposes a novel non-invasive method for assessing the vascular endothelial function 
of lower-limb arteries based on the dilation rate of air-cuff plethysmograms measured using the 
oscillometric approach. The principle of evaluating vascular endothelial function involves flow-
mediated dilation. In the study conducted, blood flow in the dorsal pedis artery was first monitored 
while lower-limb cuff pressure was applied using the proposed system. The results showed blood flow 
was interrupted when the level of pressure was at least 50 mmHg higher than the subject’s lower-limb 
systolic arterial pressure and that blood flow velocity increased after cuff release. Next, values of the 
proposed index, %ezFMDL, for assessing the vascular endothelial function of lower-limb arteries were 
determined from 327 adult subjects: 87 healthy subjects, 150 subjects at high risk of arteriosclerosis 
and 90 patients with cardiovascular disease (CAD). The mean values and standard deviations calculated 
using %ezFMDL were 30.5 ± 12.0% for the healthy subjects, 23.6 ± 12.7% for subjects at high risk of 
arteriosclerosis and 14.5 ± 15.4% for patients with CAD. The %ezFMDL values for the subjects at high 
risk of arteriosclerosis and the patients with CAD were significantly lower than those for the healthy 
subjects (p < 0.01). The proposed method may have potential for clinical application.
Arteries are composed of three layers: the tunica aventitia, the tunica media and the tunica intima. The vascular 
endothelium is the innermost layer of the tunica intima, and consists of monostratal vascular endothelial cells 
that produce various vasodilators such as nitric oxide (NO) to adjust for the coarctation of vascular vessels and 
maintain flexibility1. When vascular endothelial function deteriorates as a result of risk factors such as diabetes 
and hypertension, the flexibility of vascular vessels becomes impaired and arteriosclerosis develops2,3. Arteries in 
the lower-limbs are sites of predilection for peripheral artery disease (PAD), which is a type of advanced arterio-
sclerosis4 caused by vascular endothelial dysfunction and can result in subcutaneous tissue necrosis if treatment is 
1Academic Institute, College of Engineering, Shizuoka University, Hamamatsu, 739-8527, Japan. 2Graduate 
School of Engineering, Hiroshima University, Higashi-Hiroshima, 739-8527, Japan. 3Department of System 
Cybernetics, Faculty of Engineering, Hiroshima University, Higashi-Hiroshima, 739-8527, Japan. 4Nihon Kohden 
corporation, Tokorozawa, 359-8580, Japan. 5Department of Anesthesiology and Critical Care, Graduate School of 
Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan. 6Department of Cardiovascular 
Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan. 
7Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, 
Hiroshima University, Hiroshima, 734-8553, Japan. 8Department of Cardiovascular Physiology and Medicine, 
Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan. 9Division of 
Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, 
Hiroshima, 734-8551, Japan. Yukihito Higashi and Toshio Tsuji contributed equally to this work. Correspondence and 
requests for materials should be addressed to Harutoyo Hirano (email: hirano.harutoyo@shizuoka.ac.jp) or Y.H. 
(email: yhigashi@hiroshima-u.ac.jp) or T. Tsuji (email: tsuji@bsys.hiroshima-u.ac.jp)
Received: 22 January 2018
Accepted: 1 June 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2ScieNtific REPORTS |  (2018) 8:9263  | DOI:10.1038/s41598-018-27392-3
delayed. Arteriosclerosis of the lower-limb arteries is reportedly related to the progression of systemic cardiovas-
cular conditions such as coronary arterial disease and carotid stenosis5. Accordingly, quantitative assessment of 
vascular endothelial function in these arteries may support the early recognition and treatment of arteriosclerosis.
Numerous methods for assessing vascular endothelial function in lower-limb arteries have been proposed. As 
an example of an invasive approach, blood flow variations were measured using plethysmography after the patient 
was given a NO agonist drug or a NO antagonist drug6,7. However, invasive methods carry risk, cause patient 
discomfort and are problematic to apply because a NO agonist drug or a NO antagonist drug must be delivered 
arterially via a catheter. Meanwhile, flow-mediated dilation (FMD) is often used as a non-invasive method for 
assessing upper-limb vascular endothelial function8,9. FMD allows vascular endothelial function evaluation based 
on vascular diameter variations measured with an ultrasound device. In FMD testing, shear stress caused by 
increased blood flow after arterial avascularization and release applies a stimulus to the vascular endothelium, 
which in turn produces NO. However, the test requires an ultrasonologist with a high level of technical ability 
for accurate measurement of the patient’s vascular diameter accurately over an extended period, and its results 
depend on the patient’s blood pressure10. In addition, it is difficult to accurately measure the vascular diameter of 
lower-limb arteries with an ultrasound device because they are located deep under the skin and ultrasonic signals 
do not propagate well through biological tissues. It is therefore technically challenging to apply FMD testing to 
lower-limb arteries. With this in mind, the our research group proposed a novel method for determining the 
vascular endothelial function of upper-limb arteries easily without the use of an ultrasound device11–13. This 
technique, known as the enclosed zone FMD (ezFMD), involves the application of oscillometry (as used with 
commercial automated sphygmomanometers at patients’ homes and in hospitals) rather than vascular diameter 
measurement using an ultrasound device. In the ezFMD approach, plethysmograms are extracted using an air 
cuff attached to an upper limb, and the vascular endothelial function of the upper-limb arteries is assessed by 
calculating the difference in the maximum amplitudes of the extracted plethysmograms before and after cuff 
occlusion. The ezFMD is a noninvasive and simple method for assessing endothelial function compared to the 
FMD. Our previous studies showed that the ability of ezFMD to assess endothelial function at the upper arm was 
equal to or greater than that of FMD at the forearm and has good potential for screening with minimal technical 
requirements to assess endothelial function because there was wide variability in both ezFMD and FMD12,13. 
However, the ezFMD method has not been applied to lower-limb arteries, which are sites of predilection for 
arteriosclerosis.
Therefore, the authors propose a novel noninvasive and easy method for assessing the vascular endothelial 
function of lower limb arteries based on the ezFMD approach, which does not use an ultrasound device.
Methods
Subjects. A total of 327 adults (236 males, 91 females; mean age ± S.D.: 55.9 ± 21.2 yrs) were used for the 
lower-limb ezFMD measuring experiment. The subject breakdown is as follows: 87 healthy subjects (78 males and 
9 females; mean age ± S.D.: 30.8 ± 14.9 yrs), 150 subjects at high risk of arteriosclerosis (90 males and 60 females; 
mean age ± S.D.: 62.0 ± 16.2 yrs) and 90 patients with cardiovascular disease (CAD) (68 males and 22 females; 
mean age ± S.D.: 70.2 ± 10.3 yrs). Healthy subjects had no history of cardiovascular diseases, liver diseases, renal 
diseases, autoimmune diseases, or malignant diseases and had no coronary risk factors, including hypertension, 
dyslipidemia, diabetes mellitus, and current smoking. The subjects at high risk of arteriosclerosis were defined as 
people who were affected by one or more of the following: hypertension, diabetes, dyslipidemia, or current ciga-
rette smoking. Hypertension was defined as systolic blood pressure of >140 mmHg or diastolic blood pressure of 
> 90 mmHg, in a sitting position, on at least three different occasions14. Diabetes mellitus was defined according 
to the American Diabetes Association15. Dyslipidemia was defined according to the third report of the National 
Cholesterol Education Program16. Current smokers were defined as smokers who had smoked ≥ 1 pack-year, 
1 pack-year being defined as 20 cigarettes per day for 1 year. CAD was defined as coronary artery disease, cer-
ebrovascular disease, and PAD. Coronary artery disease included angina pectoris, myocardial infarction, and 
unstable angina. Cerebrovascular disease included ischemic stroke, hemorrhagic stroke, and transient ischemic 
attack. Patients with intermittent claudication or revascularization (surgery or catheter-based interventions), or 
limb amputation were diagnosed as PAD. Framingham risk score was calculated with points for the following 
risk factors: age, total cholesterol level, high-density lipoprotein cholesterol level, systolic blood pressure, and 
smoking status17. Estimated glomerular filtration rate was calculated using the following equation: 194 × serum 
creatinine−1.0949 × age−0.287 (× 0.739 for women)18.
In addition, the 8 males of the above healthy subjects (mean age ± S.D.: 23.1 ± 0.8 yrs) were randomly chosen 
for measuring the lower-limb blood flow and the other 5 males of the above healthy subjects (mean age ± S.D.: 
22.2 ± 0.8 yrs) were randomly selected to measure the lower-limb ezFMD of continuous days. The FMD testing 
was performed for 89 randomly chosen subjects: 8 healthy subjects (6 males and 2 females; mean age ± S.D.: 
38.2 ± 16.1 yrs), 49 subjects at high risk of arteriosclerosis (33 males and 16 females; mean age ± S.D.: 60.2 ± 16.1 
yrs), and 32 patients with CAD (29 males and 3 females; mean age ± S.D.: 66.1 ± 11.1 yrs).
Experiments were conducted in accordance with the Declaration of Helsinki. Informed consent was obtained 
from all study participants before the experiments were performed and the study was approved by the ethics com-
mittee of Hiroshima University (https://upload.umin.ac.jp. Unique identifier: UMIN000004902).
Study Protocol. The proposed system requires fulfillment of the following four criteria for application of 
ezFMD to lower-limb arteries:
 (1) The system can be used to perform lower-limb arterial blood flow occlusion and prompt post-occlusion 
reactive hyperemia.
 (2) The proposed method’s evaluation index %ezFMDL is highly reproducible.
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 (3) The %ezFMDL index shows statistically significant differences between healthy subjects and subjects at 
high risk of arteriosclerosis and between healthy subjects and patients with cardiovascular disease.
 (4) The %ezFMDL index shows a significant correlation to %ezFMDB (the index for evaluating vascular en-
dothelial function at the brachial artery) for the same healthy subjects because these subjects are consid-
ered to have normal vascular endothelial function in all arteries.
Lower-limb blood flow measuring experiment. Blood flow was observed during lower-limb ezFMD measurement 
to confirm the fulfillment of requirement (1). The target arteries for evaluation of vascular endothelial function in 
terms of lower-limb ezFMD are the anterior tibial artery, the posterior tibial artery and the fibular artery. However, 
as it is difficult to observe blood flow in these arteries with ultrasound due to their location deep below the skin, 
flow in the dorsal pedis artery (located in the periphery of the anterior tibial artery) was observed instead. Blood 
flow volume Fb(t) is often measured for observation of reactive hyperemia. The equation used here is:
F t V t D t( )
4
( ){ ( )} , (1)b b b
2pi=
where Vb(t) and Db(t) are blood flow velocity and vascular diameter, respectively. Vascular diameter needs to 
be measured to determine blood flow volume Fb(t) as Equation (1). However, it is technically difficult to track 
immediate variations in vascular diameter with a Doppler ultrasound blood flowmeter based on the echo track-
ing method while measuring cuff oscillation and during the period immediately after the release of cuff occlu-
sion. It was therefore verified that the proposed system can be used to perform blood flow occlusion and prompt 
post-occlusion reactive hyperemia in lower-limb arteries.
The chosen 8 healthy subjects were instructed to abstain from eating for at least eight hours beforehand to 
eliminate the effects of numerous factors that influence vasodilatation8. All subjects were instructed to assume a 
resting prone position for five minutes before blood flow velocity was measured. The velocity Vb(t) in the dorsal 
pedis artery was measured with a Doppler ultrasound blood flowmeter (QFM-21, Hadeco) while lower-limb 
ezFMD was measured with an ezFMD measuring device (FMD tester, Nihon Kohden). Blood flow velocity 
Vb(t), cuff pressure and oscillation were measured at 1,000 Hz using an analog-to-digital converter (CSI-360116, 
Interface), and the data obtained were saved to a PC. The root mean square (RMS) of blood flow velocity is 
calculated to evaluate blood flow variations, and RMS values calculated using the following equation from data 
collected before, during and after cuff occlusion were compared:
∫= −V T T V t dt
1 { ( )} ,
(2)
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T
T
b
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where T1, and T2 are the RMS calculation start and end times, respectively. The time ranges for calculation were 
30 seconds before occlusion, 3 minutes during occlusion and 30 seconds immediately after occlusion. Bonferroni 
correction was applied for comparison of the means of all subjects’ RMS values calculated from data collected 
before, during and after cuff occlusion.
Lower-limb ezFMD measuring experiment. Lower-limb ezFMD was measured using the protocol outlined in 
Methods Chapter to verify requirements (2)–(4). Blood pressure in these arteries was measured with a physiolog-
ical monitor (OPV1510, Nihon Kohden), and an ezFMD measuring device was used to measure oscillation and 
apply occlusion. The cuff pressure and oscillation were measured at 1000 Hz using an analog-to-digital converter 
and saved to a PC.
Paired t-testing was first performed to compare the mean of oscillation amplitudes in data collected before 
and after cuff occlusion. The testing was conducted for each mean value for the healthy subjects and the subjects 
at high risk of arteriosclerosis and those with CAD. Tukey-Kramer testing was also applied to compare the means 
calculated from all subjects’ %ezFMDL values among the healthy subjects and the subjects at high risk of arterio-
sclerosis and those with CAD to verify requirement (3).
Next, the %ezFMDLs of the selected 5 healthy males were measured on five consecutive days to verify require-
ment (2). The subjects were instructed to abstain from eating for at least eight hours before each measurement. 
The coefficient of variation value CV was calculated using %ezFMDL data collected over the five days, and the 
mean CV value for the five subjects was also calculated. CV value was determined using the following equation:
CV SD
x
, (3)=
where SD and x  are the standard variation and mean, respectively, of the %ezFMDL values measured over the five 
days. To evaluate the proposed system’s capacity for repeatability, the mean CV value for the lower-limb ezFMD meas-
ured from the five subjects was compared with the corresponding value for the brachial artery as measured from five 
other healthy males (mean age ± S.D.: 23.2 ± 0.7 yrs) using an ezFMD measuring device designed for this purpose19. 
Welch’s t-test was used to compare the mean CV value for the lower-limb ezFMD with the brachial values.
There is no index with which %ezFMDL can be compared to verify the effectiveness of the proposed system 
because no research group has proposed a non-invasive method for quantitative evaluation of lower-limb vascular 
endothelial function. However, as healthy subjects are considered to have normal vascular endothelial function in 
all arteries, a correlation between lower-limb and upper-limb artery function can be assumed (requirement (4)). 
In this experiment, both the ezFMD of the brachial artery and the lower-limb arterial ezFMD were measured 
in all subjects, and the measured %ezFMDL was statistically compared with %ezFMDB12 (representing the rate 
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of change in cuff oscillation amplitude in the brachial artery as determined using an ezFMD measuring device 
designed for this purpose). Here, upper-limb blood pressure was measured with a physiological monitor. Cuff 
pressure and oscillation were measured at 1,000 Hz using an analog-to-digital converter and saved to a PC. The 
correlation coefficient and regression lines were calculated from each subject’s %ezFMDL and %ezFMDB to ver-
ify requirement (4). Testing for no correlation was conducted to evaluate the calculated correlation coefficient. 
In addition, receiver operating characteristic (ROC) analysis20 was performed for the calculated %ezFMDL and 
%ezFMDB values to evaluate lower-limb vascular endothelial function screening capacity. %FMD, the de facto 
standard index for estimating vascular endothelial function, and the ankle brachial pressure index21 were also 
measured with an ultrasound device for FMD testing (UNEXEF-18G, Unex) and a blood pressure pulse wave 
inspection device (form PWV/ABI BP-203, Omron Colin), respectively.
Lower-limb vascular endothelial function assessment method. Intravascular pressure and external 
pressure originating from the cuff of the automated sphygmomanometer are applied to the arterial wall while 
blood pressure is measured. The maximum variation of the cuff ’s plethysmogram signals, which shows the differ-
ence between systolic and diastolic pressures, is determined under a condition in which intravascular pressure is 
approximately equal to the external pressure originating from the cuff because arterial wall compliance is maxi-
mized in this state.
Cuff plethysmogram signals are related to vascular vessel volume. Assuming that the temperature in the cuff is 
constant, the relationship between the internal cuff volume V and the internal cuff pressure P can be expressed as
× = .P V const , (4)
where the vascular volume increases by ΔV, the cuff volume decreases by ΔV and the cuff pressure increases by 
ΔP in relation to cuff oppression caused by increased cuff volume. The oscillation amplitude ΔP can be expressed 
as
+ Δ × − Δ = × .P P V V P V( ) ( ) (5)
Assuming that ΔP × ΔV is minute compared with the other terms, Equation (5) can be described as
Δ =
Δ ×
.P V P
V (6)
Therefore, if the cuff volume V and the pressure in the cuff P are constant, the oscillation amplitude ΔP is pro-
portional to the vascular volume variation ΔV. Here, vasodilation is evaluated from the oscillation amplitude ΔP.
Blood flow increases sharply after the vascular vessel is released from cuff occlusion with a level of pressure 
higher than that of systolic blood pressure for a given length of time. This physiological phenomenon is called 
reactive hyperemia22. Shear stress is generated at the boundary of the vascular endothelium in relation to the 
increased blood flow in the area of cuff occlusion. Vascular endothelial cells are stimulated due to the release of 
various vasodilators such as NO, and this NO causes increased compliance of the vascular smooth muscle in the 
tunica media. The relationship linking vascular volume variation ΔV, pulse pressure PP and arterial compliance 
C can be expressed as following23:
Δ = × .V C PP (7)
Assuming that blood pressure is equal before and after cuff occlusion, the following Equation (8) can be 
obtained from Equations (6) and (7):
Δ
Δ
=
Δ
Δ
=
P
P
V
V
C
C
,
(8)
2
1
2
1
2
1
where ΔV1 and ΔV2 are the vascular volume variation before and after cuff occlusion, C1 and C2 represent arterial 
compliance before and after cuff occlusion, and ΔP1 and ΔP2 show the oscillation amplitude before and after cuff 
occlusion. Vascular compliance variations can thus be measured by comparing the oscillation amplitude before 
and after cuff occlusion.
Figure 1 shows the proposed lower-limb ezFMD measurement system, which consists of three parts: (i) a 
measurement part for determination of cuff oscillation using the oscillometric approach; (ii) an analysis part for 
determination of vascular feature quantity from the measured oscillation; (iii) an assessment part for evaluation 
of vascular endothelial function in lower-limb arteries based on the feature quantity determined in (ii).
In the measurement part, the standard cuff used with an oscillometric automatic sphygmomanometer is 
attached to the ankle of the subject at rest in a prone position. Oscillation measurement and arterial occlusion are 
performed with the standard cuff and the mean pressure method24 result in improved repeatability in the upper 
limbs during cuff depressurization. Occlusion pressure is adjusted to a level at least 50 mmHg higher than the 
subject’s systolic arterial pressure so that arteries are completely occluded8. Cuff oscillation is first measured once, 
and occlusion is then applied for five minutes. Cuff oscillation is measured again five times at 30-second intervals 
after the release of the occlusion.
In the analysis part, the maximum amplitude per beat is determined from each oscillation measurement. With 
the proposed method, the effects of lower-limb arterial blood pressure are eliminated by applying cuff pressure 
corresponding to the subject’s blood pressure, and the vascular compliance characteristics of the arterial wall are 
extracted without the influence of this pressure. The method therefore enables evaluation of the maximum vascu-
lar compliance based on calculation to determine beat amplitudes in each oscillation measurement.
www.nature.com/scientificreports/
5ScieNtific REPORTS |  (2018) 8:9263  | DOI:10.1038/s41598-018-27392-3
In the assessment part, the rate of change in lower-limb arterial amplitude %ezFMDL is calculated using the 
maximum amplitudes observed before and after cuff occlusion in the analysis part and the following equation:
ezFMD
A
A
% 1 100,
(9)
L
post
pre
=



−



×
where Apre and Apost are the maximum amplitude before the cuff occlusion and the average of the measured 
maximum amplitude during the period from the third to the fifth measured oscillations after the cuff occlusion 
in consideration of vasodilatation response time25, respectively. After occlusion, vascular volume variation is 
considered to increase and oscillation waves are considered to expand because the NO released causes relaxation 
of the smooth muscle in the tunica media. As a result, if vascular endothelial function is normal, the maximum 
amplitude will increase after occlusion and the calculated rate of change in amplitude will be positive.
The author thus defined the index %ezFMDL for the evaluation of vascular dilatation variations before and 
after occlusion, and the proposed index was used for quantitative evaluation of lower-limb vascular endothelial 
function.
Results
Baseline clinical characteristics. The baseline clinical characteristics of the subjects are summarised in 
Table 1. The age range was 21–90 years. Of the 327 subjects, 236 (72.2%) were males and 91 (22.3%) were females. 
173 (58.1%) had hypertension, 158 (53.0%) had dyslipidemia, 73 (24.5%) had diabetes mellitus and 39 (13.2%) 
were smokers. The mean value of ezFMD was 23.0 ± 14.5%. No significant difference was found between males 
and females (23.1 ± 14.9 v.s. 22.9 ± 13.0, p = 0.90).
Lower-limb blood flow measuring experiment. Figure 2(a) shows the blood flow velocity Vb(t) meas-
ured while the lower-limb ezFMD of a healthy male subject (Sub. A) was measured. Figure 2(b) shows the calcu-
lated RMSs of blood flow velocity VbRMS before, during and after cuff occlusion as measured from a healthy subject (Sub. A). The measured blood flow velocity Vb(t) varied during the period before and after cuff occlusion due to 
the effect of the cuff pressure applied for plethysmogram extraction. Figure 2(a) shows that measured blood pres-
sure Vb(t) was approximately 0 cm/sec during cuff occlusion and increased sharply immediately afterward. 
Figure 2(b) shows that the RMS of the measured blood pressure VbRMS was close to 0 cm/sec during occlusion and increased afterward. Figure 2(c) shows the means and standard deviations of the RMS of measured blood pres-
sure VbRMS for all subjects. It can be seen that latter value was close to 0 cm/sec during cuff occlusion and signifi-cantly increased afterward compared with the corresponding value before occlusion for all subjects (p < 0.01).
Lower-limb ezFMD measuring experiment. Figure 3(a,b) show the measured cuff oscillation waveform 
and calculated amplitude value from beat to beat before and after cuff occlusion for a healthy male subject (Sub. 
A), where the amplitude was calculated from the beats within the shaded area. It can be seen that the amplitude 
was higher after occlusion than before. Figure 3(c–e) show the mean values and standard deviations calculated 
from the oscillation amplitude before and after cuff occlusion based on measurements from the healthy sub-
jects, subjects at high risk of arteriosclerosis and patients with CAD, respectively. Figure 3(c–e) indicated that 
the amplitudes after the cuff occlusion were significantly higher than those before the cuff occlusion among 
the healthy subjects, the subjects at high risk of arteriosclerosis and the patients with CAD (healthy subjects: 
p = 1.2 × 10−39, subjects at high risk of arteriosclerosis: p = 2.5 × 10−46, patients with CAD: p = 5.4 × 10−13).
Figure 4 shows that the mean values and standard deviations calculated from %ezFMDL for the healthy 
subjects, the subjects at high risk of arteriosclerosis and those with CAD were 30.5 ± 12.0%, 23.6 ± 12.7% and 
14.5 ± 15.4%, respectively. Significant differences were confirmed between the %ezFMDL of the healthy subjects 
and that of the subjects at high risk of arteriosclerosis, between that of the healthy subjects and that of the patients 
Figure 1. Overview of the proposed lower-limb ezFMD measuring system.
www.nature.com/scientificreports/
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Variables Total (n = 327)
Age, y 55.9 ± 21.2
Body mass index, kg/m2 24.0 ± 11.5
Systolic blood pressure, mmHg 133.3 ± 23.2
Diastolic blood pressure, mmHg 62.0 ± 11.0
Heart rate, bpm 66.9 ± 11.9
Ankle brachial pressure index 1.10 ± 0.14
Total cholesterol, mmol/L 182.3 ± 37.8
Triglycerides, mmol/L 121.2 ± 72.8
HDL-C, mmol/L 57.4 ± 16.1
LDL-C, mmol/L 106.6 ± 32.9
Glucose. mmol/L 110.6 ± 43.4
Hypertension, n, % 173 (58.1%)
Dyslipidemia, n, % 158 (53.0%)
Diabetes mellitus, n, % 73 (24.5%)
Smoking, n, % 39 (13.2%)
Coronary heart disease, n, % 63 (21.1%)
Cerebrovascular disease, n, % 26 (8.7%)
Peripheral artery disease, n, % 25 (8.4%)
Framingham risk score, % 15.1 ± 10.8
ezFMD, % 23.0 ± 14.5
Table 1. Clinical characteristics of the Subjects. All results are presented as mean ± S.D. or number (%). HDL-
C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ezFMD, enclosed zone 
flow-mediated dilation.
Figure 2. Blood flow velocity during lower-limb ezFMD measurement: (a) time variation of blood flow velocity 
(Sub. A), (b) RMS of blood flow velocity (Sub. A), (c) RMS of blood flow velocity (all subjects).
www.nature.com/scientificreports/
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with CAD and between that of the subjects at high risk of arteriosclerosis and that of the patients with CAD 
(healthy subjects v.s. subjects at high risk of arteriosclerosis: p = 4.1 × 10−5, healthy subjects v.s. patients with 
CAD: p = 1.0 × 10−12, subjects at high risk of arteriosclerosis v.s. patients with CAD: p = 5.7 × 10−6). The mean 
Figure 3. Measured results of cuff oscillation: (a) air-cuff oscillation and maximum amplitude measured from 
a healthy subject (Sub. A) before cuff occlusion, (b) those after cuff occlusion, (c) comparison of maximum 
amplitude between before and after cuff occlusion in healthy subjects, (d) that in subjects at high risk of 
arteriosclerosis, (e) that in patients with CAD.
Figure 4. Results of comparison for calculated %ezFMDL among healthy subjects, subjects at high risk of 
arteriosclerosis and patients with CAD.
www.nature.com/scientificreports/
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values and standard deviations of measured %FMD for the healthy subjects, subjects at high risk of arteriosclero-
sis, and those with CAD were 7.83 ± 4.42%, 4.81 ± 4.03% and 3.43 ± 2.27%, respectively. A significant difference 
was confirmed between the healthy subjects and the patients with CAD (p = 2.6 × 10−2), whereas no significant 
differences were confirmed between the healthy subjects and those at a high risk of arteriosclerosis or between 
those at a high risk of arteriosclerosis and those with CAD (healthy subjects vs. those at high risk of arterioscle-
rosis: p = 1.0 × 10−1, subjects at high risk of arteriosclerosis vs. patients with CAD: p = 5.4 × 10−2). In contrast, 
mean values of %ezFMDL for the same subjects who underwent FMD testing were 35.8 ± 10.6%, 24.1 ± 12.7%, 
and 17.6 ± 15.4%, respectively. Significant differences were confirmed among all subject groups (healthy subjects 
vs. subjects at high risk of arteriosclerosis: p = 1.8 × 10−2; healthy subjects vs. patients with CAD: p = 1.2 × 10−3; 
and subjects at high risk of arteriosclerosis vs. patients with CAD: p = 4.9 × 10−2).
Figure 5(a) shows variations in %ezFMDL over five consecutive days for all subjects. Figure 5(b) shows that the 
mean value and standard deviations of CV for the healthy subjects calculated from %ezFMDL and those of CV 
measured with the ezFMD measuring device for the brachial artery were 0.23 ± 0.15 and 0.22 ± 0.04, respectively. 
The CV calculated from %ezFMDL was thus similar to that from the brachial artery. No statistically significant 
difference was seen between the CV from %ezFMDL and that from the brachial artery.
Figure 6(a,b) show the correlation between %ezFMDB (representing the vascular endothelial function of the 
brachial artery) and %ezFMDL and between %FMD and %ezFMDL, respectively. The ratio of %ezFMDL to %ezF-
MDB for the healthy subjects, that for the subject at high risk of arteriosclerosis and that for the patient with CAD 
were 0.48, 0.31, and 0.46, respectively (p < 0.001).
Figure 7(a,b) show the results of the %ezFMDL and %ezFMDB that ROC curve analysis performed to discrim-
inate the subjects at high risk of arteriosclerosis from the healthy subjects and AUCs calculated from the full area 
under these ROC curves. Figure 7(b) indicates that the AUCs of %ezFMDL and %ezFMDB were 0.66 and 0.65, 
respectively. Figure 7(c,d) show the results of the %ezFMDL and %ezFMDB that ROC curve analysis performed to 
discriminate the patients with CAD from the healthy subjects and AUCs calculated from the full area under these 
ROC curves. Figure 7(d) indicates that the AUCs of %ezFMDL and %ezFMDB were 0.78 and 0.80, respectively.
Discussion
The blood flow was interrupted by the applied cuff pressure at least 50 mmHg higher than the subject’s lower-limb 
systolic arterial pressure as shown the measured blood flow velocity Vb(t) of a healthy male subject (Sub. A) in 
Fig. 2(a). In addition, shear stress caused by the sharp increase in blood flow velocity Vb(t) immediately after 
occlusion release may have caused vascular endothelial cell stimulation. The proposed system is capable of inter-
rupting lower-limb arterial blood flow, as the mean RMS of measured blood pressure VbRMS during cuff occlusion for all healthy subjects was sufficiently close to 0 cm/sec as shown the mean values and standard deviations of the 
RMS of measured blood pressure VbRMS for all healthy subjects in Fig. 2(c). Reactive hyperemia in the lower-limb 
vascular endothelium is also shown due to the significant increase observed in measured blood flow Vb(t) after 
cuff occlusion using the proposed system. These outcomes show that lower-limb blood flow is interrupted and the 
lower-limb vascular endothelium is stimulated using the proposed system.
The lower-limb arterial dilation after occlusion for a healthy male subject as shown in Fig. 3(a,b). The ampli-
tude values measured from the healthy subjects, the subjects at high risk of arteriosclerosis and the patients 
with CAD significantly increased just after cuff occlusion release as shown in Fig. 3(c–e). This is because the 
Figure 5. Five-day variation of measured %ezFMDL in each healthy subject: (a) time variations in %ezFMDL, 
(b) comparison of calculated coefficients of variation.
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lower-limb vascular compliance of the healthy subjects increased well after cuff occlusion release in association 
with sufficient release of NO, and additionally because that of the subjects at high risk of arteriosclerosis and the 
patients with CAD also increased in association with NO release even though their lower-limb vascular endothe-
lial function may have been weaker than that of the healthy subjects.
The %ezFMDL of the patients with CAD was significantly lower than that of the healthy subjects and that of 
the subjects at high risk of arteriosclerosis was significantly lower than that of the healthy subjects as shown in 
Fig. 4, which satisfies requirement (3) listed in Study Protocol section. This result indicates that the amount of NO 
produced after cuff occlusion was reduced because of lower-limb vascular endothelial dysfunction.
The CV of %ezFMDL over a period of five consecutive days exhibited large variations among the healthy sub-
jects as shown in Fig. 5. However, it can be seen that the repeatability of the proposed system is almost equal to 
that of the previous index ezFMDB. The CV of the proposed system was also better than that of %FMD, which is 
the current de facto standard for non-invasive evaluation of vascular endothelial function. The proposed system 
therefore satisfied requirement (2) listed in Study Protocol section and may be considered useful in the assess-
ment of lower-limb vascular endothelial function.
The index %ezFMDL exhibited a moderate correlation with %ezFMDB in the healthy subjects and the patients 
with CAD as shown in Fig. 6. These outcomes indicate that %ezFMDL satisfied requirement (4) listed in Study 
Protocol section and that ezFMD can be used for quantitative assessment of lower-limb vascular endothelial 
function.
The effectiveness of using %ezFMDL to discriminate patients with CAD from healthy subjects was equal to 
that of %ezFMDB as shown in Fig. 7. The discrimination method between patients with CAD and healthy sub-
jects using %ezFMDL for the diagnosis is to use the cutoff value calculated from the ROC analysis because it is an 
indicator to distinguish between positive and negative test outcomes. A %ezFMDL value of 22.6% was optimal 
for distinguishing between patients with CAD and healthy individuals in this study. Peripheral artery disease is 
known as an occlusive arterial disease that most commonly affects the legs. It is thus important to measure the 
vascular endothelial function at the lower-limb arteries. the proposed system is highly promising for assess-
ment to discriminate lower-limb vascular endothelial dysfunction from normal vascular endothelial function in 
lower-limb arteries.
In conclusion, this paper proposes a novel system for evaluating vascular endothelial function in lower-limb 
arteries based on ezFMD. The results reported that the system is capable of prompting reactive hyperemia and 
stimulating the vascular endothelium in lower-limb arteries. A lower-limb ezFMD measuring experiment was 
conducted on healthy subjects whose vascular endothelial function was normal. The results showed that the 
measured amplitude of cuff oscillation was significantly higher after cuff occlusion than before for all healthy 
subjects, and that the repeatability of the proposed index for assessing vascular endothelial function was equal 
Figure 6. Statistical comparison of indices: (a) comparison between the ezFMD of the upper and lower limbs 
and (b) comparison between FMD and ezFMD testing of the lower limbs.
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to or better than that of the previous index. The proposed index showed a significant correlation with that of the 
brachial artery. As the system outlined here has high discrimination ability for lower-limb vascular endothelial 
dysfunction and lower-limb arteriosclerosis, it was considered effective.
Study Limitations
The discrimination accuracy between the healthy group and the risk factor group using %ezFMDL requires fur-
ther investigation for use as a diagnostic marker. Nitric oxide bioavailability testing was not performed in this 
study. The assessment of NOx, a marker of nitric oxide bioavailability26, would provide more information about 
ezFMD functionality. The currently proposed system for measuring lower-limb ezFMD has high variability. An 
improved system for measuring the vascular endothelial function of the lower-limb artery with high accuracy is 
required.
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